Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2015

View Archived Issues

PCORI approves USD 83 million to fund patient-centered clinical effectiveness research studies

LDC and Infinity Pharmaceuticals to cooperate in oncology drug discovery and development

Novavax receives Gates Foundation grant to develop RSV vaccine; reports phase I and II results

Amydis Diagnostics awarded NIA-NIH grant for technology to detect Alzheimer's disease

Heraeus Medical and OrthoCyte agree to develop stem cell based bone graft product

Cloud Pharmaceuticals and THERAMetrics collaborate in orphan CNS diseases

Astellas and Chromocell sign license and collaboration agreement in neuropathic pain

Downregulation of lysyl oxidase prevents vascular lesions in diabetic retinopathy

Aspen Park Pharmaceuticals acquires drug to treat castration-resistant prostate cancer

Epicardial Fstl1 promotes cardiomyocyte regeneration after myocardial infarction

Naproxcinod superior to naproxen in mouse model of DMD

GSK exercises option to license inhaled therapeutics under Liquidia collaboration

The Leukemia & Lymphoma Society commits new funding to support cancer research

European Union funds 4SC research project EMTherapy

Phase III METEOR trial data: cabozantinib in advanced kidney cancer

Effect of TRL-1068 on biofilms

Bristol-Myers Squibb receives FDA approval for Opdivo + Yervoy in metastatic melanoma

XBiotech's 514G3 receives FDA fast track designation for serious infections

Seno Medical Instruments completes final phase of PIONEER study

Breast Cancer Awareness Month: Testing a new approach

Xoma licenses first-in-class anti-TGF-beta antibody program to Novartis

Amicus Therapeutics completes acquisition of Scioderm

Roche and Siena Biotech report BACE1 inhibitors

reMYND presents compounds for protein-misfolding disorders

Boehringer Ingelheim presents SYK inhibitors

Bayer presents new soluble guanylate cyclase activators

Otologic licenses sensory hair cell regeneration technology from Hough Ear Institute

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...